Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in cancer patients.
Yana DebieJonas R M Van AudenaerdeTimon VandammeLieselot CroesLaure-Anne TeuwenLise VerbruggenGreetje VanhoutteElly MarcqLisa VerheggenDebbie Le BlonBart PeetersMaria E GoossensPieter PannusKevin K AriënSébastien AnguilleAnnelies JanssensHans PrenenEvelien L J SmitsChristof VulstekeEva LionMarc PeetersPeter A van DamPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
In cancer patients who received double-dose ChAdOx1, a third heterologous dose of BNT162b2 was able to close the gap in antibody response.